Pharmaceuticals News

BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the...

Mendus AB (“Mendus” publ; IMMU.ST), ett bioläkemedelsföretag fokuserat på att förbättra överlevnadsresultat för cancerpatienter med tumörrecidiv genom cellbaserade immunterapier, tillkännagav idag...

Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on improving survival outcomes for cancer patients with tumor recurrence through cell-based immunotherapies, today announced its...

- En bonne voie pour élargir le portefeuille de produits afin d'atteindre un portefeuille cible de 30 programmes d'ici 2024. - Poursuite du déploiement commercial de Sotalol IV aux États-Unis et de...

- On track to broaden product pipeline to meet a target portfolio of 30 programs by 2024- Continued commercial rollout of Sotalol IV in US and Maxigesic® IV - Focused entry into US market with...

After seven years as President of NIBR and a member of the ECN, Dr. Bradner will pursue a next chapter of scientific contribution and leadership outside of NovartisBuilding on NIBR foundation, Dr....

Ergebnisse der VISION-DMD-Studie, welche die Wirksamkeit und Sicherheit von Vamorolone im Vergleich zu Placebo und zur Standardbehandlung mit Prednison zeigen, wurden in JAMA Neurology veröffentlicht...

Results from the VISION-DMD study showing efficacy and safety of vamorolone compared to placebo and to standard of care, prednisone, has been published in JAMA NeurologySafety analysis on bone...

Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financingDebuted as...

Secured funding of approximately $185 million in gross proceeds through the merger with OACB (the “Business Combination”) and private placement investment in public equity (PIPE) financingDebuted as...